Grifols (GRFS) Current Assets (2009 - 2025)
Grifols (GRFS) posted Current Assets of $5.9 billion for Q4 2025, down 3.51% quarter-over-quarter from $6.1 billion in Q4 2024, and down 3.51% year-on-year from $6.1 billion in Q4 2024.
Grifols (GRFS) Current Assets (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Current Assets for 16 consecutive years, with $5.9 billion the latest figure, recorded in Q4 2025.
- Current Assets for Q4 2025 came in at $5.9 billion, down 3.51% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.9 billion (down 3.51% YoY), and the FY2025 annual result was $5.9 billion, up 21775.4% from the prior year.
- Current Assets was $5.9 billion for Q4 2025 at Grifols, down from $6.1 billion in the prior quarter.
- Over five years, Current Assets peaked at $6.6 billion in Q4 2023 and troughed at $4.8 billion in Q4 2022.
- Average Current Assets over 5 years is $5.9 billion, with a median of $6.1 billion recorded in 2024.
- Year-over-year, Current Assets soared 67.05% in 2021 and declined 24.08% in 2022.
- Over 5 years, Current Assets stood at $6.3 billion in 2021, then slipped by 24.08% to $4.8 billion in 2022, then soared by 37.84% to $6.6 billion in 2023, then declined by 7.21% to $6.1 billion in 2024, then retreated by 3.51% to $5.9 billion in 2025.
- Per Business Quant data, the three most recent Current Assets figures were $5.9 billion in Q4 2025, $6.1 billion in Q4 2024, and $6.6 billion in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 54.84 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 59.17 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 5.91 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.91 Bn |
| Dec 31, 2024 | 6.12 Bn |
| Dec 31, 2023 | 6.60 Bn |
| Dec 31, 2022 | 4.79 Bn |
| Dec 31, 2021 | 6.30 Bn |
| Dec 31, 2020 | 3.77 Bn |
| Sep 30, 2020 | 4.26 Bn |
| Mar 31, 2020 | 4.04 Bn |
| Dec 31, 2019 | 5.94 Bn |
| Sep 30, 2019 | 4.07 Bn |
| Mar 31, 2019 | 3.97 Bn |
| Dec 31, 2018 | 3.98 Bn |
| Sep 30, 2018 | 3.52 Bn |
| Jun 30, 2018 | 3.52 Bn |
| Mar 31, 2018 | 3.64 Bn |
| Dec 31, 2017 | 3.47 Bn |
| Jun 30, 2017 | 3.13 Bn |
| Dec 31, 2016 | 3.37 Bn |
| Sep 30, 2016 | 3.30 Bn |
| Jun 30, 2016 | 3.30 Bn |